First-in-Human test of DNA shot aims to train immune system against hepatitis c
NCT ID NCT02772003
Summary
This is an early-stage safety study testing a new type of DNA vaccine designed to help the body's immune system fight chronic Hepatitis C virus (HCV) infection. The trial will enroll 33 adults with a specific type of HCV (genotype 1) to determine safe doses and see if the vaccine triggers an immune response. Researchers will monitor for side effects and check if the vaccine reduces the amount of virus in the blood.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Case Western Reserve University
Cleveland, Ohio, 44106, United States
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980, United States
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
-
Temple University Hospital
Philadelphia, Pennsylvania, 19140, United States
-
University of Puerto Rico
San Juan, 00936, Puerto Rico
Conditions
Explore the condition pages connected to this study.